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Abstract
Purpose The risk of febrile neutropenia (FN) in cancer pa-
tients receiving chemotherapy is mainly due to the type of
chemotherapy regimen and the presence of specific risk fac-
tors in patients. The recent trend of using a dose-dense treat-
ment schedule has enhanced the risk of FN. In the present
prospective study, we evaluated the feasibility of a reduction
of duration of therapy with colony-stimulating factor (G-CSF)
in a dose-dense regimen.
Methods Between June 2002 and December 2011, 107 pa-
tients with a new diagnosis of non-Hodgkin lymphoma (NHL)
receiving dose-dense chemotherapy, every 14 days, were in-
cluded in the study. The primary endpoint was defined as the
completion of planned chemotherapy cycles as scheduled.
Secondary endpoints were median number of administered
G-CSF doses (vials), incidence of FN, hospitalization and
toxicity.
Results The planned chemotherapy cycles (primary endpoint)
were completed by 84.1 % of patients. The median number of
G-CSF (lenograstim) doses administered for each patient was
24 (range 10–35), which corresponds to a median of five vials
(range 0–10) for each cycle. Grades 3–4 toxicities, related to
G-CSF administration, included neutropenia and thrombocy-
topenia (14.0 and 1.9 %, respectively). No grades 3–4 bone
pain was detected. The incidence of FN and hospitalization
was 9.3 % (10/107) and 4.5 % (5/107), respectively.
Conclusions Reduced dosage of G-CSF allows dose-dense
chemotherapy scheduling, limits exposure to G-CSF and also
represents an opportunity for cost savings.
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Introduction
Chemotherapy-induced febrile neutropenia (FN) is one of the
most common adverse events in cancer patients receiving
myelosuppressive drugs [1]. The risk of FN is mainly due to
the type of chemotherapy regimen and the presence of specific
risk factors (age, gender, comorbidities) [2]. The risk of FN is
increased by the recent trend of using a dose-dense treatment
schedule compared to a standard-dose chemotherapy regimen
[2].
Prophylactic administration of granulocyte colony-
stimulating factor (G-CSF) provides protection for patients
at risk of FN in reducing hospital admissions, antibiotic usage
and the need for dose reductions or delays during chemother-
apy administration, which are associated with poorer onco-
logical outcome [1, 2].
The intensity (frequency and total dose) of chemotherapy is
a major factor to be taken into account when assessing the risk
of FN and the possible administration of G-CSF prophylaxis.
As suggested by the European Organisation for Research and
Treatment of Cancer (EORTC) guidelines, G-CSF should be
administered as primary prophylaxis for FN in cancer patients
receiving dose-dense chemotherapy [2].
According to international guidelines [2, 3] and
registrational clinical trials [4–6], prophylaxis with daily sub-
cutaneous (s.c.) administration of G-CSF (filgrastim or
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lenograstim) should start from 24 to 72 h after chemotherapy
and continued until sufficient/stable post-nadir absolute neu-
trophil count (ANC) recovery [1]. Alternatively, a single s.c.
administration of pegfilgrastim (6 mg) is considered equally
effective and comparable to 11 injections of daily G-CSF
[4–6]. The return to normal range of the absolute ANC re-
quires approximately 9–14 daily G-CSF injections per che-
motherapy cycle [1]. A large survey has challenged these
indications and highlighted that the mean G-CSF administra-
tion is 5.5 days: only 9.3 % of patients exceed 7 days, and 6 %
exceed 10 days, confirming that the timing and doses of
adequate daily G-CSF prophylaxis are still debatable [7].
In clinical practice, alternative G-CSF schedules have been
tested, suggesting that reduction of the number of G-CSF
administrations without altering the outcome is feasible
[8–10]. A shorter G-CSF schedule may reduce the risk and
severity of short-term side effects and is also more cost-
effective [11–15]. For patients receiving dose-dense chemo-
therapy regimens, the days of G-CSF administration should be
planned accurately since it should be given before nadir onset
and far from chemotherapy administration, avoiding the toxic
priming effect of G-CSF [1]. The choice of timing of G-CSF
administration, compared to chemotherapy, is chosen by the
physician considering the risks, benefits and costs. Based on
these considerations, we evaluated the feasibility of adminis-
tering fewer doses of G-CSF (lenograstim) during treatment of
non-Hodgkin lymphoma (NHL) with a dose-dense rituximab-
cyclophosphamide, vincristine, doxorubicin, prednisone (R-
CHOP)-14 regimen.
Methods
This was a single-centre, prospective, non-comparative study
conducted in the HaematologyUnit of Careggi Hospital (Flor-
ence, Italy) according to Good Clinical Practice guidelines
and the Declaration of Helsinki and was approved by the local
ethics committee. Patients with histologically or cytologically
confirmed NHL, at any stage, and eligible for a first-line R-
CHOP regimen every 14 days were enrolled in the study.
Patients were required to be >18 years of age, with an Eastern
Cooperative Oncology Group performance status of zero to
one and normal hepatic and renal functions. Normal cardiac
(left ventricular ejection fraction), neutrophil count of
≥1,500×109/l, haemoglobin of ≥9 g/dl and platelet count of
>100,000 were required before the first cycle. Patient candi-
dates for multiple-day/high-dose chemotherapy or bone
marrow/peripheral blood stem cell transplantation and pa-
tients who were pregnant or breastfeeding were excluded.
Informed consent was obtained from all patients at study
entry. The R-CHOP regimen was rituximab the day before
chemotherapy (day 0) and cyclophosphamide of 750 mg/m2,
doxorubicin of 50 mg/m2 and vincristine of 1.4 mg/m2
(max. 2 mg) on day 1 plus prednisone of 100 mg orally
for 5 days. The R-CHOP regimen was administered every
14 days for six cycles. Lenograstim was administered sub-
cutaneously at a dose of 263 mcg from day 5 to day 11
(seven vials). Blood cell counts were obtained the day of
rituximab administration (on day 0 of each cycle), and if
patients reached a number of leucocytes over 20,000/mm3,
the lenograstim dose was reduced by one vial (Fig. 1). This
reduction was applied in a sequential order.
The primary endpoint of the study was completion of
planned chemotherapy cycles, defined as the percentage of
patients experiencing dose reduction or treatment delays due
to haematological toxicity. Secondary endpoints included the
proportion of patients needing hospitalization and those
experiencing febrile episodes, defined as a single temperature
of >38.3 °C (101 °F) or a sustained temperature of ≥38 °C
(100.4 °F) for more than 1 h.
Secondary endpoints included evaluation of complete re-
mission rate, progression-free survival (PFS) and overall sur-
vival (OS). Disease status was assessed between the third and
fourth R-CHOP cycles and at the end of the therapy. Response
to therapy was evaluated with standard response criteria for
lymphoma [16]. PFS was defined as the time between the first
chemotherapy administration and the occurrence of disease
relapse, disease progression, death from any cause or last
follow-up. OS was defined as the time from first chemother-
apy administration until death or the date of last follow-up
when the patient was known to be alive.
Toxicity was graded using the Common Terminology
Criteria for Adverse Events (CTCAE) v.4.03. All adverse
events attributed to G-CSF administration that occurred dur-
ing the study, as observed by the investigator or reported by
the subject, were recorded.
If a cycle was delayed for seven or more days because of
myelosuppression caused by the prior cycle, doses of chemo-
therapy agents were reduced by 25%. In case of intolerance or
in the case of two delays, treatment was switched to R-CHOP-
21. Endpoints were evaluated during all planned R-CHOP-
14 cycles. Patients were followed up for clinical response to
chemotherapy and survival until progression or death.
Descriptive statistics refer to all included patients. For
continuous variables, the median, minimum and maximum
values were calculated. For each discrete variable, the number
of cases in each category, in relation to all cases with non-
missing values of that variable, was calculated.
Sample size was calibrated with the aim to obtain primary
endpoint estimate with adequate precision. A total sample size
of 110 patients ensures a precision quantified in the order of
15 % assuming that a primary endpoint estimate equals to
80 %. Precision is measured by the width of the two-sided
95 % confidence interval of the primary endpoint rate. The
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Score-Wilson Confidence Interval Formula implemented
in PASS 2008 software was employed for sample size
computations [17].
The distribution of leukocytes, neutrophils and platelet data
were descriptively analysed using box-plot graphs. The
boundary of the box closest to zero indicates the 25th percen-
tile, a line within the box marks the median and the boundary
of the box farthest from zero indicates the 75th percentile.
Whiskers above and below the box indicate the 90th and 10th
percentiles. In addition, the 95th and 5th percentiles were
graphed as points.
Results
Between June 2002 and December 2011, 107 patients
with a new diagnosis of NHL (92.5 % DLBCL, 7.5 %
follicular lymphoma grade IIIb) were included in the
study. The median age was 61 years (range 20–75);
29 % of patients had a high-intermediate or high inter-
national prognostic index (IPI).
Bulky disease, elevated LDH and symptoms were present
in 34.6 % (37/107), 31.8 % (34/107) and 42.1 % (45/107) of
patients, respectively. Twenty-two patients (20.6 %) had bone
marrow involvement. The median number of administered R-
CHOP cycles was 6 (range 3–6). The main patient character-
istics are reported in Table 1.
All patients received a daily administration of G-CSF ac-
cording to protocol (Fig. 1). The median number of
lenograstim doses (vials) administered for each patient was
24 (range 10–35), which corresponds to a median of five vials
(range 0–10) for each cycle.
In the first 10 patients, we used seven vials of G-CSF after
each cycle of chemotherapy (from day 5 to day 11). As the
treatment was well-tolerated (according to a median ANC
count of 6,100, range 3,140–10,600 mm3), we prospectively
decided to reduce the number of vials of G-CSF to five (from
day 6 to day 10).
The planned chemotherapy cycles of R-CHOP were com-
pleted by 84.1 % of patients as scheduled; 15.9 % of cases
experienced treatment delay due to neutropenia and thrombo-
cytopenia in 15 (14.0 %) and 2 (1.9 %) patients, respectively.
Three patients (2.8 %) switched to R-CHOP-21 scheduling
because of poor tolerance to the dose-dense chemotherapy or
more than one delay. The incidence of febrile episodes was
9.3 % (10/107), and 4.5 % (5/107) of patients required hospi-
talization due to febrile neutropenia.
Haematological recovery was regularly assessed in each
patient before rituximab administration, and the median
values of leucocytes, neutrophils, haemoglobin and thrombo-
cytes were 3,550 mm3 (range 400–13,600), 54 % (range 10–
79), 10.7 g/dL (range 5.8–15.5) and 152,000 mm3 (range
43,000–328,000), respectively. The box-plot for leukocytes,
neutrophils and platelets is shown in Fig. 2.
Clinical response was observed in 96.2 % (103/107) of
patients: the complete response rate was 86.9 % (93/107),
while the partial response rate was 9.3 % (10/107). After a
Fig. 1 Treatment schedule of the first chemotherapy administration and
study evaluations. The red boxes indicate days of chemotherapy admin-
istration; yellow boxes indicate days of G-CSF administration, and yel-
low-shaded boxes (day 5 and day 11) indicate the potential days of G-CSF
reduction according CBC results; CBC, complete blood count; R, ritux-
imab; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone
Table 1 Patient
characteristics
DLBCL diffuse large B
cell lymphoma, FL-3b
follicular lymphoma at
stage 3b, IPI internation-
al prognostic index
Variable % (N)
Non-Hodgkin lymphoma 100 (107)
Age (years)
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median follow-up of 25 months (range 4–90 months), PFS
was 77.6 % (83/107) and overall survival was 86.9 % (93/
107).
Grades 3–4 toxicities related to chemotherapy have been
neutropenia (14.0 %) and thrombocytopenia (1.9 %). No
grades 3–4 toxicity has been reported related to G-CSF ad-
ministration; particularly, no grades 3–4 bone pain was
observed.
Discussion
FN is a major cause of morbidity and mortality in patients
receiving chemotherapy, leading to a decrease in the dose of
cytotoxic agents, delay in the intervals between cycles and
limiting the dose intensity of the treatment [1]. Dose-dense
chemotherapy is increasingly used in an attempt to improve
long-term clinical outcomes [1].
According to EORTC guidelines, prophylaxis with G-CSF
is suggested in a dose-dense chemotherapy regimen, but
timing and doses of the most appropriate G-CSF administra-
tion is still a matter of debate [1]. Generally, the correct G-CSF
prophylaxis should consider three factors: (i) day of chemo-
therapy administration, (ii) day of nadir onset (iii) and FN risk
factors [18].
It is possible that the timing of G-CSF application, when
optimally timed, might help to alleviate the harsh trough in
neutrophil counts caused by chemotherapy [19].
There is clinical evidence for the efficacy of G-CSF in
supporting delivery of dose-dense R-CHOP in both young
and elderly NHL patients [1]. G-CSF is a fundamental drug
during R-CHOP-14, as the short treatment cycle of 14 days
would not otherwise allow sufficient time for bone marrow
recovery between cycles [1]. Consistent with these data, we
assessed the efficacy of lower lenograstim doses as FN pro-
phylaxis in high-risk NHL patients receiving dose-dense R-
CHOP regimens. In our study, a median of five (range 0–10)
injections of lenograstim per cycle allowed the majority of
patients (84.1 %) to complete the planned R-CHOP regimens.
The amount of G-CSF also lowered the risk of febrile episodes
(9.3 %), hospitalizations (4.7 %) and grade 4 neutropenia
(14 %).
Recently, in the oncology setting, Badalamenti and col-
leagues also defined a reduced dosage of G-CSF as FN
prophylaxis in soft tissue sarcoma patients [20]. The authors
found that 5-day lenograstim treatment is efficient as prophy-
laxis of FN and allowed the maintenance of chemotherapy
dose intensity.
No randomized clinical trials, in either pegylated or
daily G-CSG forms (filgrastim and lenograstim), have
assessed the lowest fully effective dose of G-CSF needed
for FN prophylaxis [4–6]. G-CSF administration has been
protracted until post-nadir ANC recovery, but the exact
time of nadir onset for the chemotherapy regimen remains
unknown [21]. Recently, Ria and colleagues defined the
nadir onset of most commonly used chemotherapy regi-
mens in a haematologic setting in order to help physicians
tailor the correct timing and duration of G-CSF prophy-
laxis, attempting to define the optimal timing and duration
of G-CSF prophylaxis [21].
We speculate that, in our study, five doses of G-CSF
were effective in allowing completion of R-CHOP cycles
in NHL because we started before nadir onset (at day 9),
as recently reported by Ria and colleagues [21], and far
from chemotherapy administration, avoiding the priming
effect of G-CSF [1]. The lowest fully effective dose of
G-CSF allows limited exposure to G-CSF, which may be
associated with potential long-term adverse events
[8–10], and also represents an opportunity for cost savings
[22, 23].
Vainas and colleagues have recently developed a new
method for personalizing combined chemotherapeutic and
G-CSF schedules for the most efficacious chemotherapy.
Their method could reduce neutropenia by tailoring effica-
cious cytotoxic and supportive treatments, while minimizing
side effects [18].
Future and randomized trials should clarify the exact
role of G-CSF, the magnitude of its clinical benefit in
terms of survival, the most appropriate dosage (number
of vials/pegylated or not pegylated form) and time of
administration.
In our study and recent publications [20, 21], the
possibility to reduce number of G-CSF seems to be safe,
efficacious and cost-saving (number of vials and use of
pegylated), although more randomized trials are needed to
define the correct timing and dosage of G-CSF to prevent
FN, evaluating also quality of life, in patients receiving
dose-dense chemotherapy.
Fig. 2 Box-plots for leukocytes, neutrophils and platelets evaluated at
each cycle before rituximab administration of the R-CHOP regimen
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